The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.本案揭示內容提供與計劃性死亡-1 (PD-1)蛋白質結合之抗體藥劑。明確提供特定免疫球蛋白重鏈多肽及免疫球蛋白輕鏈多肽序列。亦提供相關核酸、載體、組成物及使用抗PD-1抗體藥劑治療對PD-1抑制起反應之病症或疾病(諸如癌症或感染性疾病)的方法。
